[Translational Research in Brain Tumors:Development towards Integrated Precision Medicine]

Area of Science:

• Neuro-oncology
• Translational Medicine
• Precision Oncology

Background:

• Malignant brain tumors, especially diffuse high-grade gliomas, have poor outcomes due to treatment resistance and heterogeneity.
• Current treatments (surgery, radiotherapy, chemotherapy) and molecular classification show limited success in overcoming these challenges.
• Integrating molecular insights into clinical practice remains a significant hurdle.

Purpose of the Study:

• To establish a unified translational platform integrating intraoperative diagnostics, molecular imaging, and patient-derived models.
• To create a multidimensional precision medicine framework for malignant brain tumors.
• To accelerate the development of personalized therapies by bridging basic science and clinical practice.

Main Methods:

• Utilizing rapid intraoperative molecular diagnostics for real-time decision-making.
• Employing molecular imaging (e.g., amino acid and hypoxia PET) for noninvasive evaluation of tumor biology and heterogeneity.
• Leveraging patient-derived xenograft models and primary cell cultures for functional analysis of drug sensitivity and resistance.

Main Results:

• Demonstrated the value of integrating intraoperative diagnostics, molecular imaging, and patient-derived models.
• Established a framework that integrates temporal, spatial, and functional information for a comprehensive understanding of tumor characteristics.
• Highlighted the potential for real-time surgical and therapeutic decision-making based on molecular alterations.

Conclusions:

• An integrated precision medicine strategy combining diagnostics, imaging, and models can overcome challenges in treating malignant brain tumors.
• This multidimensional approach facilitates the development of more effective personalized therapies.
• Close collaboration across disciplines and efficient translation of research are crucial for advancing patient care.